Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

Dupilumab is associated with a reduced risk of peripheral vascular disease, deep vein thrombosis, hypertension, type 2 diabetes mellitus, obesity, and hyperlipidemia within the first year of treatment ...

Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published ...

Dupilumab treatment of atopic dermatitis (AD) resulted in long-term skin improvements linked to changes in skin’s the molecular composition, according to study findings published in the Journal of ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

Upadacitinib outperformed dupilumab for clinically meaningful pruritus improvement among patients with moderate to severe atopic dermatitis as early as day 2 of treatment. As pruritus is the chief ...

in pediatric patients receiving dupilumab for atopic dermatitis (AD). The findings, published in Clinical & Experimental Allergy, emphasize the need for heightened vigilance in monitoring ocular ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...